Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595618 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 932
- Enrollment target
NCT03595618: Completed Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03595618 is a Phase 2 study that has completed, run by Lakefront Biotherapeutics. The registered enrollment target is 932 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595618, a Phase 2 study, has completed, sponsored by Lakefront Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 932 participants
- Enrollment target
Study Summary
This study is a phase 2, 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.
Interventions
- DRUG Placebo
- DRUG GLPG1972
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 932 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2020-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03595618
The ClinicalTrials.gov registry entry for NCT03595618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 932 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03595618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03595618 about?
NCT03595618 is a clinical study titled "A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis". This study is a phase 2, 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.
What is the current status of trial NCT03595618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 932 participants. The study started on 2018-08-14. Estimated completion is 2020-07-14.
What interventions are being tested in trial NCT03595618?
The interventions under investigation include: Placebo (DRUG), GLPG1972 (DRUG).
Who is sponsoring clinical trial NCT03595618?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.